Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Glioblastoma 5Gliosarcoma 4Squamous Cell Carcinoma of Head and Neck 3Glioma 3Brain Neoplasms 3Treatment-Refractory Solid Tumors 2Salivary Gland Neoplasms 2Central Nervous System Neoplasms 2Tongue Neoplasms 1Oligodendroglioma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1HPV-Negative Squamous Cell Carcinoma 1Esthesioneuroblastoma, Olfactory 1Ependymoma 1Carcinoma, Non-Small-Cell Lung 1Bites and Stings 1Astrocytoma 1Advanced Solid Tumors 1

Interventions

Injections 18Carboplatin 14Docetaxel 11pembrolizumab 8durvalumab 7Cisplatin 6linifanib 5Paclitaxel 5Nivolumab 5zimberelimab 4talazoparib 4olaparib 4Panobinostat 4Itraconazole 4Bevacizumab 4tremelimumab 3sintilimab 3depatuxizumab 3atezolizumab 3ST 1481 3S 1 (combination) 3Rifampin 3Pemetrexed 3Oxaliplatin 3Fluorouracil 3Everolimus 3Drug Therapy 3trifluridine tipiracil drug combination 2trametinib 2toripalimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Solid Tumors × Hydroxyurea × Clear all
NCT01521299 2012-08-28

A Dose Escalation Study of Hydroxyurea in Combination With SCH900776 in Advanced Malignant Solid Tumors

Dartmouth-Hitchcock Medical Center

Phase 1 Withdrawn
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡